HPV-Vaccines

• Other Authors: Calagna, Gloria (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Subjects: Medicine; HPV; HPV vaccine; social media; mobile phone; HPV vaccine intervention; RE-AIM Framework; human papillomavirus; vaccination coverage; recipient-oriented interventions; provider-oriented interventions; systematic review; human papillomavirus vaccination; adverse effects; orthostatic dysregulation; chronic regional pain syndrome; cognitive dysfunction; HPV vaccination; men who have sex with men; online health promotion; outcome and process evaluation; Human Papillomavirus; barriers; pharmacists; vaccination; cervical cancer; cervical intraepithelial neoplasia; E6 oncoprotein; E7 oncoprotein; therapeutic vaccine; DNA vaccine; DNA therapeutic vaccine; pharmacy; vaccine referral; family medicine; obstetrics and gynecology; HPV vaccine barriers; provider perspectives; vaccines; AEFIs; causality assessment; dosing schedule; dosing interval; 9-valent; low adherence; HPV serum antibodies; L1 HPV; 9-valent vaccination; squamous intraepithelial neoplasia; HPV vaccine knowledge; HPV vaccine awareness; Kazakhstan; cervical cancer prevention; human papilloma virus; health behaviour; vaccine hesitancy; membranous nephropathy; p16 INK4a; mass spectrometry; vaccine effectiveness; vaccine impact; real-world evidence; systematic literature review
• Online Access: DOAB: download the publication; DOAB: description of the publication

Human papillomavirus (HPV) is closely linked with the pathogenesis of cervical cancer and many other cancers. HPV vaccines are vaccines that prevent infection from certain types of human papillomavirus. However, despite the various prevention strategies and treatments, such as HPV screening, prophylactic HPV vaccines, surgery, radiotherapy, and chemotherapy, the disease burden remains heavy worldwide. Currently, three types of prophylactic vaccines-quadrivalent HPV vaccines, bivalent HPV vaccines, and a new nonavalent HPV vaccine-are commercially available. Although these vaccines protect against 90% of HPV infections, their capacity to eliminate pre-existing infections is limited. In this Topical Collection, we aim to systematically cover the progress, current status, and future prospects of various vaccines being developed for the prevention and treatment of HPV-associated lesions and cancers.